Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

The Cambridge-based drugmaker also said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug Administration.

Patients taking doses of Aduhelm available through the commercial market can continue until November. A company representative said there are about 2,500 people worldwide taking Aduhelm.

Biogen said it will turn its focus to other treatments for the fatal, mind-robbing disease. The company also is helping Japanese drugmaker Eisai sell another Alzheimer’s treatment, Leqembi, which received full FDA approval last summer.

WynnBet, Betr look to exit Mass. mobile sports betting

Two of the eight mobile sports betting platforms operating in Massachusetts are planning to stop taking bets here, shrinking a market that has been largely dominated by two companies since it launched in the state less than a year ago.

WynnBet confirmed Wednesday that it plans to cease online wagering in Massachusetts and Betr announced last week that it would not renew its temporary license to take bets in Massachusetts.

Both departures will go before the Mass. Gaming Commission during a meeting Thursday.

The end date of WynnBet operations in Massachusetts depends on the commission’s approval and that the app’s shutdown will not have any effect on the WynnBet Sportsbook at Encore Boston Harbor in Everett, the company said.

The mobile sportsbook, aligned with Encore parent company Wynn Resorts, has already shut down its online wagering operations in seven other states.